Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 4/2019

25.06.2019 | Research Article

Improving medication safety in oncology care: impact of clinical pharmacy interventions on optimizing patient safety

verfasst von: Himanshu Patel, Parthasarathi Gurumurthy

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background Adverse drug reactions (ADRs) monitoring in cancer patients is important to ensure early detection, effective management and possible prevention subsequently. Objectives This study was conducted to detect and monitor ADRs to anti-cancer agents, and to assess impact of clinical pharmacists (CPs)’ interventions in minimizing ADRs to anti-cancer agents. Setting Private, specialty oncology care hospital in South India. Methods CPs prospectively followed cancer patients admitted to inpatient wards and treated at ambulatory care in order to identify ADRs, for a period of 3 years. Identified/reported ADRs were discussed with concerned oncologists and/or nurses, documented electronically and assessed further for their causality, severity, preventability and grading. Based on study findings during year 1, interventions (educational, therapeutic and system based) were developed by CPs and implemented in order to minimize preventable ADRs. Impact of CPs’ interventions was studied during year 2 and year 3. Main outcome measure(s) Preventable factors contributing to ADRs and percentage of preventable ADRs before and after CPs’ interventions. Results A total of 1279 ADRs were reported in 1133 patients from a cohort of 1328 patients. Vomiting (23.22%), alopecia (9.53%), diarrhoea (8.67%) and myelosuppression (7.42%) were the common ADRs reported. Inappropriate administration frequency and regimen of anti-emetics (22%), lack of/suboptimal supportive care (18%) and administration errors (16%) were identified as common contributing (preventable) factors for ADRs in year 1. Percentage of preventable ADRs was 81% during year 1 (pre-intervention), and 45% and 34% in year 2 and year 3 respectively (post-interventions). Conclusion Interventions by CPs helped to minimize preventable ADRs to anti-cancer agents.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017;35(12):1341–67.CrossRefPubMed Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017;35(12):1341–67.CrossRefPubMed
3.
Zurück zum Zitat Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, Bonhomme C, Bugat R, Montastruc JL. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol. 1997;53(1):19–22.CrossRefPubMed Lapeyre-Mestre M, Gary J, Machelard-Roumagnac M, Bonhomme C, Bugat R, Montastruc JL. Incidence and cost of adverse drug reactions in a French cancer institute. Eur J Clin Pharmacol. 1997;53(1):19–22.CrossRefPubMed
4.
Zurück zum Zitat Peppercorn J. Financial toxicity and societal costs of cancer care: distinct problems require distinct solutions. Oncologist. 2017;22(2):123–5.CrossRefPubMedPubMedCentral Peppercorn J. Financial toxicity and societal costs of cancer care: distinct problems require distinct solutions. Oncologist. 2017;22(2):123–5.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kukec RR, Grabnar I, Vovk T, Mrhar A, Kovac V, Cufer T. Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. Radiol Oncol. 2015;49(2):173–80.CrossRefPubMedPubMedCentral Kukec RR, Grabnar I, Vovk T, Mrhar A, Kovac V, Cufer T. Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. Radiol Oncol. 2015;49(2):173–80.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in Namibia: a cost-utility analysis. Drug Saf. 2016;39(9):859–72.CrossRefPubMed Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, et al. Active surveillance versus spontaneous reporting for first-line antiretroviral medicines in Namibia: a cost-utility analysis. Drug Saf. 2016;39(9):859–72.CrossRefPubMed
7.
Zurück zum Zitat Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Indian J Med Paediatr Oncol. 2016;37(1):42.CrossRefPubMedPubMedCentral Chopra D, Rehan HS, Sharma V, Mishra R. Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Indian J Med Paediatr Oncol. 2016;37(1):42.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Belachew SA, Erku DA, Mekuria AB, Gebresillassie BM. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study. Drug Healthc Patient Saf. 2016;8:83.CrossRefPubMedPubMedCentral Belachew SA, Erku DA, Mekuria AB, Gebresillassie BM. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study. Drug Healthc Patient Saf. 2016;8:83.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez E. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm. 2014;71:960–5.CrossRefPubMed Wong SF, Bounthavong M, Nguyen C, Bechtoldt K, Hernandez E. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. Am J Health Syst Pharm. 2014;71:960–5.CrossRefPubMed
10.
Zurück zum Zitat Caracuel F, Banos U, Herrera MD, Ramirez G, Munoz N. Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. Int J Clin Pharm. 2014;36:287–90.CrossRefPubMed Caracuel F, Banos U, Herrera MD, Ramirez G, Munoz N. Influence of pharmaceutical care on the delayed emesis associated with chemotherapy. Int J Clin Pharm. 2014;36:287–90.CrossRefPubMed
11.
Zurück zum Zitat Michaud LB. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm. 2010;67(7 Suppl 3):S20–30.CrossRefPubMed Michaud LB. Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm. 2010;67(7 Suppl 3):S20–30.CrossRefPubMed
12.
Zurück zum Zitat Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. In: Mayo clinic proceedings, vol. 87, no. 10. Elsevier; 2012. p. 935–43. Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. In: Mayo clinic proceedings, vol. 87, no. 10. Elsevier; 2012. p. 935–43.
13.
Zurück zum Zitat Sharma A, Kumari KM, Manohar HD, Bairy KL, Thomas J. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India. Perspect Clin Res. 2015;6(2):109.CrossRefPubMedPubMedCentral Sharma A, Kumari KM, Manohar HD, Bairy KL, Thomas J. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care hospital in South India. Perspect Clin Res. 2015;6(2):109.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83–94.CrossRefPubMed Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83–94.CrossRefPubMed
15.
Zurück zum Zitat US Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. US Department of Health and Human Services. National Institutes of Health. National Cancer Institute. 2009. US Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. US Department of Health and Human Services. National Institutes of Health. National Cancer Institute. 2009.
17.
Zurück zum Zitat Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMed Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.CrossRefPubMed
18.
Zurück zum Zitat Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm. 1992;49(9):2229–32.CrossRef Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm. 1992;49(9):2229–32.CrossRef
19.
Zurück zum Zitat Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.PubMed Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27(6):538.PubMed
20.
Zurück zum Zitat Patel H, Gurumurthy P. Implementation of clinical pharmacy services in an academic oncology practice in India. J Oncol Pharm Pract. 2017;1:1078155217739684. Patel H, Gurumurthy P. Implementation of clinical pharmacy services in an academic oncology practice in India. J Oncol Pharm Pract. 2017;1:1078155217739684.
21.
Zurück zum Zitat Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer. 2005;41(2):199–205.CrossRefPubMed Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer. 2005;41(2):199–205.CrossRefPubMed
22.
Zurück zum Zitat Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12(9):1143–50.CrossRefPubMed Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12(9):1143–50.CrossRefPubMed
23.
Zurück zum Zitat Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232–43.CrossRefPubMed Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232–43.CrossRefPubMed
25.
Zurück zum Zitat LeBaron VT, Palat G, Sinha S, Chinta SK, Jamima BJ, Pilla UL, et al. Recommendations to support nurses and improve the delivery of oncology and palliative care in India. Indian J Palliat Care. 2017;23(2):188–98.CrossRefPubMedPubMedCentral LeBaron VT, Palat G, Sinha S, Chinta SK, Jamima BJ, Pilla UL, et al. Recommendations to support nurses and improve the delivery of oncology and palliative care in India. Indian J Palliat Care. 2017;23(2):188–98.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Ulas A, Silay K, Akinci S, Dede DS, Akinci MB, Sendur MA, et al. Medication errors in chemotherapy preparation and administration: a survey conducted among oncology nurses in Turkey. Asian Pac J Cancer Prev. 2015;16:1699–705.CrossRefPubMed Ulas A, Silay K, Akinci S, Dede DS, Akinci MB, Sendur MA, et al. Medication errors in chemotherapy preparation and administration: a survey conducted among oncology nurses in Turkey. Asian Pac J Cancer Prev. 2015;16:1699–705.CrossRefPubMed
27.
Zurück zum Zitat Saini VK, Sewal RK, Ahmad Y, Medhi B. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian J Pharm Sci. 2015;77(6):687.CrossRefPubMedPubMedCentral Saini VK, Sewal RK, Ahmad Y, Medhi B. Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian J Pharm Sci. 2015;77(6):687.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Vijayalaxmi MK, Palatty PL, Bhat P, Dinesh M. A comparative assessment of the ADR profile in various anti-cancer regimens excluding gastro-intestinal and haematological toxicity at a tertiary care centre. J Clin Diagn Res. 2011;5:1209–13. Vijayalaxmi MK, Palatty PL, Bhat P, Dinesh M. A comparative assessment of the ADR profile in various anti-cancer regimens excluding gastro-intestinal and haematological toxicity at a tertiary care centre. J Clin Diagn Res. 2011;5:1209–13.
29.
Zurück zum Zitat Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer. 2004;12(9):626–33.PubMed Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer. 2004;12(9):626–33.PubMed
30.
Zurück zum Zitat Sano HS, Waddell JA, Solimando DA Jr, Doulaveris P, Myhand R. Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. J Oncol Pharm Pract. 2005;1:21–30.CrossRef Sano HS, Waddell JA, Solimando DA Jr, Doulaveris P, Myhand R. Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost. J Oncol Pharm Pract. 2005;1:21–30.CrossRef
Metadaten
Titel
Improving medication safety in oncology care: impact of clinical pharmacy interventions on optimizing patient safety
verfasst von
Himanshu Patel
Parthasarathi Gurumurthy
Publikationsdatum
25.06.2019
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 4/2019
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00860-0

Weitere Artikel der Ausgabe 4/2019

International Journal of Clinical Pharmacy 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.